ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (2): 143-150.doi: 10.6040/j.issn.1673-3770.0.2022.016
• 综述 • Previous Articles
AI Ziqin1,2, LI Junzheng1,2,3
CLC Number:
| [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:10.3322/caac.21660 [2] Fitzmaurice C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: a systematic analysis for the Global Burden of Disease study[J]. J Clin Oncol, 2018, 36(15_suppl): 1568. doi:10.1200/jco.2018.36.15_suppl.1568 [3] Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis[J]. Oncologist, 2010, 15(9): 994-1001. doi:10.1634/theoncologist.2009-0289 [4] Cohen N, Fedewa S, Chen AY. Epidemiology and demographics of the head and neck cancer population[J]. Oral Maxillofac Surg Clin North Am, 2018, 30(4): 381-395. doi:10.1016/j.coms.2018.06.001 [5] Liu WL, Qdaisat A, Zhou SH, et al. Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers[J]. Head Neck, 2021, 43(2): 613-621. doi:10.1002/hed.26510 [6] Gau M, Karabajakian A, Reverdy T, et al. Induction chemotherapy in head and neck cancers: results and controversies[J]. Oral Oncol, 2019, 95: 164-169. doi:10.1016/j.oraloncology.2019.06.015 [7] Baudelet M, van den Steen L, Tomassen P, et al. Very late xerostomia, dysphagia, and neck fibrosis after head and neck radiotherapy[J]. Head Neck, 2019, 41(10): 3594-3603. doi:10.1002/hed.25880 [8] Coley WB. Ⅱ. contribution to the knowledge of sarcoma[J]. Ann Surg, 1891, 14(3): 199-220. doi:10.1097/00000658-189112000-00015 [9] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. doi:10.6004/jnccn.2020.0012 [10] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi:10.1038/nrclinonc.2017.148 [11] Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70(2): 86-104. doi:10.3322/caac.21596 [12] Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer[J]. Cancer Treat Rev, 2020, 84: 101977. doi:10.1016/j.ctrv.2020.101977 [13] O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167. doi:10.1038/s41571-018-0142-8 [14] Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282. doi:10.1038/nrc.2018.11 [15] Pauken KE, Lagattuta KA, Lu BY, et al. TCR-sequencing in cancer and autoimmunity: barcodes and beyond[J]. Trends Immunol, 2022, 43(3): 180-194. doi:10.1016/j.it.2022.01.002 [16] Zhu YT, Liu JY. The role of neoantigens in cancer immunotherapy[J]. Front Oncol, 2021, 11: 682325. doi:10.3389/fonc.2021.682325 [17] Chen YP, Wang YQ, Lv JW, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy[J]. Ann Oncol, 2019, 30(1): 68-75. doi:10.1093/annonc/mdy470 [18] Seliger B, Massa C, Yang B, et al. Immune escape mechanisms and their clinical relevance in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2020, 21(19): 7032. doi:10.3390/ijms21197032 [19] Lee MY, Allen CT. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer[J]. Head Neck, 2020, 42(9): 2722-2733. doi:10.1002/hed.26158 [20] Zhang XH, Shi MQ, Chen TL, et al. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy[J]. Mol Ther Nucleic Acids, 2020, 22: 298-309. doi:10.1016/j.omtn.2020.08.030 [21] Yao Y, Chen CL, Yu D, et al. Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy[J]. Allergy, 2021, 76(2): 456-470. doi:10.1111/all.14639 [22] Brooks JM, Menezes AN, Ibrahim M, et al. Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer[J]. Clin Cancer Res, 2019, 25(17): 5315-5328. doi:10.1158/1078-0432.CCR-18-3314 [23] Takahashi H, Sakakura K, Ida S, et al. Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma[J]. Cancer Sci, 2022, 113(1): 53-64. doi:10.1111/cas.15195 [24] Albers AE, Qian X, Kaufmann AM, et al. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer[J]. Sci Rep, 2018, 8(1): 10716. doi:10.1038/s41598-018-29067-5 [25] Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy[J]. J Immunol Res, 2020: 5825401. doi:10.1155/2020/5825401 [26] Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments[J]. Nat Rev Immunol, 2021, 21(2): 83-100. doi:10.1038/s41577-020-00479-7 [27] Garbuglia AR, Lapa D, Sias C, et al. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease[J]. Front Immunol, 2020, 11: 188. doi:10.3389/fimmu.2020.00188 [28] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2): e00046-e00019. doi:10.1128/CMR.00046-19 [29] Diana G, Corica C. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? [J]. Oral Oncol, 2021, 115: 105168. doi:10.1016/j.oraloncology.2020.105168 [30] Roman BR, Aragones A. Epidemiology and incidence of HPV-related cancers of the head and neck[J]. J Surg Oncol, 2021, 124(6): 920-922. doi:10.1002/jso.26687 [31] Giuliano AR, Wilkin T, Bautista OM, et al. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men[J]. Contemp Clin Trials, 2022, 115: 106592. doi:10.1016/j.cct.2021.106592 [32] Morse MA, Gwin WR 3rd, Mitchell DA. Vaccine therapies for cancer: then and now[J]. Target Oncol, 2021, 16(2): 121-152. doi:10.1007/s11523-020-00788-w [33] Stern PL. Key steps in vaccine development[J]. Ann Allergy Asthma Immunol, 2020, 125(1): 17-27. doi:10.1016/j.anai.2020.01.025 [34] Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378. doi:10.1038/s41568-021-00346-0 [35] Tran T, Blanc C, Granier C, et al. Therapeutic cancer vaccine: building the future from lessons of the past[J]. Semin Immunopathol, 2019, 41(1): 69-85. doi:10.1007/s00281-018-0691-z [36] Julian R, Savani M, Bauman JE. Immunotherapy approaches in HPV-associated head and neck cancer[J]. Cancers, 2021, 13(23): 5889. doi:10.3390/cancers13235889 [37] Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management[J]. Nat Rev Clin Oncol, 2022, 19(5): 306-327. doi:10.1038/s41571-022-00603-7 [38] Wang RJ, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge[J]. Cancer Lett, 2020, 471: 88-102. doi:10.1016/j.canlet.2019.11.039 [39] Shibata H, Zhou LY, Xu N, et al. Personalized cancer vaccination in head and neck cancer[J]. Cancer Sci, 2021, 112(3): 978-988. doi:10.1111/cas.14784 [40] Stephens AJ, Burgess-Brown NA, Jiang SS. Beyond just peptide antigens: the complex world of peptide-based cancer vaccines[J]. Front Immunol, 2021, 12: 696791. doi:10.3389/fimmu.2021.696791 [41] Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022. doi:10.1074/mcp.R120.002309 [42] Gaglione R, Pane K, Dell'Olmo E, et al. Cost-effective production of recombinant peptides in Escherichia coli[J]. N Biotechnol, 2019, 51: 39-48. doi:10.1016/j.nbt.2019.02.004 [43] Li M, Josephs RD, Daireaux A, et al. Structurally related peptide impurity identification and accurate quantification for synthetic oxytocin by liquid chromatography-high-resolution mass spectrometry[J]. Anal Bioanal Chem, 2021, 413(7): 1861-1870. doi:10.1007/s00216-021-03154-5. [44] Li WY, Separovic F, O'brien-Simpson NM, et al. Chemically modified and conjugated antimicrobial peptides against superbugs[J]. Chem Soc Rev, 2021, 50(8): 4932-4973. doi:10.1039/d0cs01026j. [45] Wanning S, Süverkrüp R, Lamprecht A. Impact of excipient choice on the aerodynamic performance of inhalable spray-freeze-dried powders[J]. Int J Pharm, 2020, 586: 119564. doi:10.1016/j.ijpharm.2020.119564. [46] Bowen WS, Svrivastava AK, Batra L, et al. Current challenges for cancer vaccine adjuvant development[J]. Expert Rev Vaccines, 2018, 17(3): 207-215. doi:10.1080/14760584.2018.1434000. [47] Gouttefangeas C, Rammensee HG. Personalized cancer vaccines: adjuvants are important, too[J]. Cancer Immunol Immunother, 2018, 67(12): 1911-1918. doi:10.1007/s00262-018-2158-4. [48] Chen XT, Yang J, Wang LF, et al. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives[J]. Theranostics, 2020, 10(13): 6011-6023. doi:10.7150/thno.38742. [49] Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol, 2021, 18(4): 215-229. doi:10.1038/s41571-020-00460-2. [50] Fries CN, Curvino EJ, Chen JL, et al. Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health[J]. Nat Nanotechnol, 2021, 16(4): 1-14. doi:10.1038/s41565-020-0739-9. [51] Isidro-Llobet A, Kenworthy MN, Mukherjee S, et al. Sustainability challenges in peptide synthesis and purification: from R&D to production[J]. J Org Chem, 2019, 84(8): 4615-4628. doi:10.1021/acs.joc.8b03001. [52] Yoshitake Y, Fukuma D, Yuno A, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS[J]. Clin Cancer Res, 2015, 21(2): 312-321. doi:10.1158/1078-0432.CCR-14-0202. [53] Yang MC, Yang A, Qiu J, et al. Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant[J]. Cell Biosci, 2016, 6: 17. doi:10.1186/s13578-016-0083-9. [54] Ogasawara M, Miyashita M, Yamagishi Y, et al. Phase Ⅰ/Ⅱ pilot study of wilms' tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer[J]. Ther Apher Dial, 2019, 23(3): 279-288. doi:10.1111/1744-9987.12831. [55] Hobernik D, Bros M. DNA vaccines-how far from clinical use? [J]. Int J Mol Sci, 2018, 19(11): 3605. doi:10.3390/ijms19113605. [56] Song Q, Zhang CD, Wu XH. Therapeutic cancer vaccines: from initial findings to prospects[J]. Immunol Lett, 2018, 196: 11-21. doi:10.1016/j.imlet.2018.01.011. [57] Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies[J]. Vaccines, 2019, 7(2): 37. doi:10.3390/vaccines7020037. [58] Wen R, Umeano AC, Kou Y, et al. Nanoparticle systems for cancer vaccine[J]. Nanomedicine(Lond), 2019, 14(5): 627-648. doi:10.2217/nnm-2018-0147. [59] Chai SJ, Fong SCY, Gan CP, et al. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients[J]. Hum Vaccin Immunother, 2019, 15(1): 167-178. doi:10.1080/21645515.2018.1520584. [60] Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor[J]. Curr Cancer Drug Targets, 2007, 7(7): 633-642. doi:10.2174/156800907782418310. |
| [1] | PANG Chong, BIAN Sainan, ZHANG Bing, YIN Xu, LU Yingxia, YE Pengfei, WANG Zhan, ZHAO Jing, GAO Yan, GUAN Kai. Short-term effect of Dermatophagoides farinae specific sublingual immunotherapy for children with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 70-74. |
| [2] | LI Menghui, ZHI Lili, QI Kaiwen, WANG Shanshan, GAO Qian, BU Meiling,. Clinical research of subcutaneous immunotherapy on children with allergic asthma caused by dust mites and combined with mold allergen [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(1): 75-80. |
| [3] | WEI Ya'nan,CHEN Xi. Progress in chemotherapy and targeted drug therapy for locally advanced head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 118-124. |
| [4] | ObjectiveThe aim of this study was to provide new perspectives and targets for the treatment of HNSCC by screening differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma(HNSCC)using bioinformatics. MethodsThe chip dataset, GSE109756, was downloaded from the GEO database, and the online analysis tool, GEO2R, was used to screen differentially expressed genes in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The DAVID 6.8 and STRING online software were used to analyze the function of the differentially expressed genes, their pathway enrichment, and their protein interactions. Cytoscape was used to visualize and analyze the protein interactions. The online analysis tool, X2K, was used to find the transcription factors, the kinases of differentially expressed genes, and their mutual regulatory relationship with the targeted genes. ResultsNinety-one differentially expressed genes, including 50 up-regulated and 41 down-regulated genes(P<0.05; | logFC | > 1), were found in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The GO and KEGG pathway analyses suggested that these differentially expressed genes were mainly enriched with immunomodulation, extracellular matrix, and other processes. Through the construction of a protein-protein interaction network, we screened CD163, VSIG4, and 3 other core differentially expressed genes(P<0.05), which were up-regulated after cetuximab treatment. In addition, our analysis shows that transcription factors, including SUZ12, TP63, and ESR1, played a key role in cetuximab treatment(P<0.05)and MAPK14, CDK1, and MAPK1 were the most important kinases during the process(P<0.05). ConclusionCD163, VSIG4, and the aforementioned transcription factors and protein kinases may be involved in the biological processes that underlie cetuximab treatment of HNSCC. This study provides new perspectives to facilitate further understanding of the biological mechanism that underlies cetuximab treatment of HNSCC and the exploration of the effectiveness of HNSCC treatment.. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformaticsYU Kena1, SUN Kaiyue2, ZHANG Jie1, JIN Peng1 1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China; 2. Shandong Provincial Otorhinolaryngology Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, Shandong, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 117-124. |
| [5] | ZHANG Guiyang, HUANG He, XIAN Zhi, ZHANG Hanwen, XIE Guicai. Evaluation of clinical effects of sublingual immunotherapy with Dermatophagoides farinae drops in patients of different age groups with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 60-65. |
| [6] | Xi CHEN,Mingzhe QIAO. Progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 42-48. |
| [7] | Kai GUAN,Lianglu WANG. Overall diagnosis and treatment strategy for allergic diseases related to hay fever [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 13-19. |
| [8] | Qianhui QIU,Junxiao GAO. Synchronous control and long-term efficacy of specific immunotherapy for allergic rhinitis and asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 33-37. |
| [9] | CAO Cheng, XU Yu. Clinical compliance and related factors to sublingual immunotherapy in patients with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 114-118. |
| [10] | WANG Tan, WU Ke, LI Lianqing, GONG Lili. Factors associated with systemic adverse reactions after subcutaneous immunotherapy injections and treatment options [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 71-74. |
| [11] | WU Jing, LIU Yehai. Targeted therapy for head and neck squamous cell carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 97-102. |
| [12] | CHEN Ming, YU Xuefei. Opinions on the treatment of chronic rhinosinusitis with allergic rhinitis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(3): 18-22. |
| [13] | QIN Gang, LIANG Zhuoping. Status of immunotherapy in allergic fungal rhinosinusitis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(3): 23-26. |
| [14] | WU Xiangping. Influence of patient management on the clinical effect of sublingual dermatophagoides farinae drops in patients [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(3): 68-72. |
| [15] | ZHAO Jincheng, SHI Ying, ZHANG Ying, JIA Zhanhong, MA Xin, ZHANG Jingqiu, WU Zaijun, WANG Yu. Expression and methylation patterns of CDH13 in human head and neck squamous carcinoma cells. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 60-63. |
|
||